Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin

Kardiologiia

Volumn 48, Issue 3, 2008, Pages 52-57

  Mikheeva, I A ^a   Kropacheva, E S ^a   Ignat'ev, I V ^a   Bulytova, I M ^a   Ramenskaia, G V ^a   Sychev, D A ^a   Dobrovol'skii A B ^a   Panchenko, E P ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; DNA; UNSPECIFIC MONOOXYGENASE; WARFARIN;

ARTICLE; BLEEDING; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK FACTOR; THROMBOSIS; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; DNA; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 48849099268     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)